
Please try another search
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Name | Age | Since | Title |
---|---|---|---|
Julie O'Neill | 59 | 2017 | Director |
Paul-Henri Lambert | 86 | - | Member of the Scientific Advisory Board |
Ravi Madduri Rao | 58 | 2021 | Independent Director |
Daniel B. Soland | 69 | 2015 | Independent Director |
Michel de Rosen | 74 | 2018 | Independent Chairman of the Board |
Jean-François Nicolas | - | 2019 | Member of Scientific Advisory Board |
Emma Guttman-Yassky | - | 2019 | Member of Scientific Advisory Board |
Hugh A. Sampson | 76 | 2015 | Scientific Adviser to the CEO & Chairman of Scientific Advisory Board |
Miriam Merad | - | 2019 | Member of Scientific Advisory Board |
Betty A. Diamond | - | 2021 | Member of Scientific Advisory Board |
Mailys Ferrere | 63 | 2012 | Director |
Timothy E. Morris | 64 | 2021 | Independent Director |
Daniel Tassé | 65 | 2018 | CEO & Director |
Adora Ndu | 44 | 2021 | Independent Director |
Michael J. Goller | 50 | 2015 | Director |
Jim Krueger | - | 2019 | Member of Scientific Advisory Board |
Daniele Guyot-Caparros | 67 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review